{"id":568730,"date":"2026-10-05T12:22:49","date_gmt":"2026-10-05T10:22:49","guid":{"rendered":"https:\/\/medizinonline.com\/?p=568730"},"modified":"2026-10-05T15:34:30","modified_gmt":"2026-10-05T13:34:30","slug":"mavenclad-est-une-option-therapeutique-importante-et-tres-efficace-qui-doit-etre-integree-tot-dans-levaluation-du-rapport-benefices-risques-en-cas-de-sep-rr-active","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/mavenclad-est-une-option-therapeutique-importante-et-tres-efficace-qui-doit-etre-integree-tot-dans-levaluation-du-rapport-benefices-risques-en-cas-de-sep-rr-active\/","title":{"rendered":"\u00abMAVENCLAD\u00ae est une option th\u00e9rapeutique importante et tr\u00e8s efficace, qui doit \u00eatre int\u00e9gr\u00e9e t\u00f4t dans l\u2019\u00e9valuation du rapport b\u00e9n\u00e9fices\/ risques en cas de SEP-RR active\u00bb"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>MAVENCLAD\u00ae (comprim\u00e9s de cladribine) est admis par les caisses-maladie en cas de scl\u00e9rose en plaques r\u00e9currente-r\u00e9mittente (SEP-RR) hautement active et d\u00e9sormais \u00e9galement en cas de SEP-RR active<sup>1,*<\/sup>. L\u2019extension de l\u2019autorisation met une autre option th\u00e9rapeutique tr\u00e8s efficace \u00e0 disposition des personnes concern\u00e9es par la SEP-RR, et ce d\u00e9j\u00e0 \u00e0 un stade pr\u00e9coce de l\u2019\u00e9volution de la maladie<sup>2, 3<\/sup>. Le Prof. Dr Klaus Schmierer (Queen Mary University of London, Angleterre) explique dans cet entretien quels sont les patients qui peuvent particuli\u00e8rement en b\u00e9n\u00e9ficier, quel r\u00f4le joue l\u2019instauration pr\u00e9coce du traitement et comment le traitement par MAVENCLAD\u00ae se distingue des autres strat\u00e9gies th\u00e9rapeutiques en continu.<\/strong><\/p>\n\n\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fmavenclad-est-une-option-therapeutique-importante-et-tres-efficace-qui-doit-etre-integree-tot-dans-levaluation-du-rapport-benefices-risques-en-cas-de-sep-rr-active%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>MAVENCLAD\u00ae (comprim\u00e9s de cladribine) est admis par les caisses-maladie en cas de scl\u00e9rose en plaques r\u00e9currente-r\u00e9mittente (SEP-RR) hautement active et d\u00e9sormais \u00e9galement en cas de SEP-RR active1,*. L\u2019extension de l\u2019autorisation&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fmavenclad-est-une-option-therapeutique-importante-et-tres-efficace-qui-doit-etre-integree-tot-dans-levaluation-du-rapport-benefices-risques-en-cas-de-sep-rr-active%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":17461,"featured_media":568740,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Contenu sponsoris\u00e9: MAVENCLAD\u00ae (comprim\u00e9s de cladribine) en cas de forme active de SEP-RR","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11549,11345,11539,11383],"tags":[],"powerkit_post_featured":[],"class_list":["post-568730","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-contenu-des-partenaires","category-interviews-fr","category-neurologie-fr","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-10-12 17:16:56","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/568730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/17461"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=568730"}],"version-history":[{"count":4,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/568730\/revisions"}],"predecessor-version":[{"id":568821,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/568730\/revisions\/568821"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/568740"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=568730"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=568730"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=568730"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=568730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}